CLINICAL TRIALS PROFILE FOR FIRAZYR
✉ Email this page to a colleague
All Clinical Trials for FIRAZYR
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00912093 ↗ | A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3) | Completed | Shire | Phase 3 | 2009-07-16 | This study is being conducted to evaluate the efficacy and safety of icatibant compared to placebo in patients experiencing acute attacks of hereditary angioedema (HAE). |
| NCT00997204 ↗ | EASSI - Evaluation of the Safety of Self-Administration With Icatibant | Completed | Jerini AG | Phase 3 | 2009-09-25 | This study is being conducted to explore the clinical safety, local tolerability, convenience and effectiveness of self-treatment of hereditary angioedema (HAE) attacks with subcutaneous injections of icatibant. |
| NCT00997204 ↗ | EASSI - Evaluation of the Safety of Self-Administration With Icatibant | Completed | Shire | Phase 3 | 2009-09-25 | This study is being conducted to explore the clinical safety, local tolerability, convenience and effectiveness of self-treatment of hereditary angioedema (HAE) attacks with subcutaneous injections of icatibant. |
| NCT01386658 ↗ | A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema | Completed | Shire | Phase 3 | 2012-01-27 | HGT-FIR-086 is a multicenter, open-label, non-randomized, single-arm study to evaluate the Pharmacokinetics, tolerability,safety, and efficacy on reproductive hormones, of a single subcutaneous (SC) administration of icatibant in approximately 30 pediatric subjects with Hereditary Angioedema (HAE) during an initial acute attack. |
| NCT01457430 ↗ | Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE | Completed | Shire Human Genetic Therapies, Inc. | Phase 4 | 2011-12-01 | The investigators propose a study to evaluate the safety, local tolerability, convenience, and efficacy of self-administered Icatibant for the treatment of acute attacks of hereditary angioedema. The investigators believe that self administration with Icatibant for treatment of an acute attack of angioedema will not change the time to complete or near complete resolution of symptoms compared to treatment with Icatibant in a medical facility. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for FIRAZYR
Condition Name
| Condition Name for FIRAZYR | |
| Intervention | Trials |
| Hereditary Angioedema | 3 |
| Hereditary Angioedema (HAE) | 2 |
| ACE Inhibitor-associated Angioedema | 1 |
| Angiotensin Converting Enzyme Inhibitor Induced Angioedema | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for FIRAZYR
Trials by Country
Clinical Trial Progress for FIRAZYR
Clinical Trial Phase
Clinical Trial Sponsors for FIRAZYR
Sponsor Name
